{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T22:53:31Z","timestamp":1785365611235,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Retinopathy of prematurity (ROP) is potentially blinding, but screening and timely treatment can stop its progression. The data on treatment outcomes of ROP from Central and Eastern Europe are scarce. Therefore, we aimed to analyze the latest results of ROP management in Poznan medical center to update the data from this world region. In the years 2016\u20132019, 178 patients (350 eyes) received treatment for ROP (6.1% of the screened population). The mean gestational age was 26\u00a0weeks (range 22\u201331\u00a0weeks), the mean birth weight was 868\u00a0g (range 410\u20131890\u00a0g). The most frequent ROP stage at treatment was zone II, stage 3\u2009+\u2009(34.9%). As the first line of treatment, 115 infants (226 eyes, 64.6%) underwent laser photocoagulation (LP); 61 infants (120 eyes, 34.3%) received intravitreal ranibizumab injections (IVR); and 2 infants (4 eyes, 0.6%) were treated simultaneously with LP and IVR. One hundred twenty-six eyes (36%) of 63 patients required retreatment: 20.4% treated with LP and 66.7% treated with IVR. Retinal detachment occurred in 14 eyes (4%). The incidence of ROP, ROP requiring treatment, and reoccurrence rates are higher in the Polish population than in Western Europe and the USA. The identified treatment patterns find increasing use of anti-VEGF agents.<\/jats:p>","DOI":"10.1038\/s41598-021-83985-5","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T11:04:11Z","timestamp":1614251051000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Management of retinopathy of prematurity (ROP) in a Polish cohort of infants"],"prefix":"10.1038","volume":"11","author":[{"given":"Anna","family":"Chmielarz-Czarnoci\u0144ska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Pawlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawid","family":"Szpecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneta","family":"Chor\u0119ziak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Szymankiewicz-Br\u0119borowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Gotz-Wi\u0119ckowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,25]]},"reference":[{"key":"83985_CR1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0002-9394(42)92088-9","volume":"25","author":"TL Terry","year":"1942","unstructured":"Terry, T. L. Extreme prematurity and fibroblastic overgrowth of persistent vascular sheath behind each crystalline lens from the Massachusetts Eye and Ear Infirmary. Am. J. Ophthalmol. 25, 203\u2013204 (1942).","journal-title":"Am. J. Ophthalmol."},{"key":"83985_CR2","unstructured":"G\u0142\u00f3wny Urz\u0105d Statystyczny\/Rocznik Demograficzny 2019 Demographic Yearbook 2019. Warsaw: Central Statistical Office (2019). https:\/\/stat.gov.pl\/obszary-tematyczne\/roczniki-statystyczne\/roczniki-statystyczne\/rocznik-demograficzny-2019,3,13.html (Accessed 27 April 2020)."},{"key":"83985_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.preteyeres.2017.09.002","volume":"62","author":"T Chan-Ling","year":"2018","unstructured":"Chan-Ling, T., Gole, G. A., Quinn, G. E., Adamson, S. J. & Darlow, B. A. Pathophysiology, screening and treatment of ROP: A multi-disciplinary perspective. Prog. Retin. Eye Res. 62, 77\u2013119 (2018).","journal-title":"Prog. Retin. Eye Res."},{"key":"83985_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.5114\/ko.2020.94207","volume":"2020","author":"A Gotz-Wi\u0119ckowska","year":"2020","unstructured":"Gotz-Wi\u0119ckowska, A., Bakunowicz-\u0141azarczyk, A., Hautz, W., Filipek, E. & Niwald, A. M. Polish Ophthalmological Society revised guidelines for the management of retinopathy of prematurity. Klin. Oczna 2020, 14\u201316 (2020).","journal-title":"Klin. Oczna"},{"key":"83985_CR5","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/archopht.123.7.991","volume":"123","author":"International Committee for the Classification of Retinopathy of Prematurity","year":"2005","unstructured":"International Committee for the Classification of Retinopathy of Prematurity. The International Classification of Retinopathy of Prematurity Revisited. Arch. Ophthalmol. 123, 991 (2005).","journal-title":"Arch. Ophthalmol."},{"key":"83985_CR6","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"Early Treatment for Retinopathy Of Prematurity Cooperative Group","year":"2003","unstructured":"Early Treatment for Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: Results of the early treatment for retinopathy of prematurity randomized trial. Arch. Ophthalmol 121, 1684\u20131694 (2003).","journal-title":"Arch. Ophthalmol"},{"key":"83985_CR7","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1136\/bjophthalmol-2015-307263","volume":"100","author":"G Holmstr\u00f6m","year":"2016","unstructured":"Holmstr\u00f6m, G. et al. Five years of treatment for retinopathy of prematurity in Sweden: Results from SWEDROP, a national quality register. Br. J. Ophthalmol. 100, 1656\u20131661 (2016).","journal-title":"Br. J. Ophthalmol."},{"key":"83985_CR8","doi-asserted-by":"publisher","first-page":"e744","DOI":"10.1111\/aos.13069","volume":"94","author":"JM Walz","year":"2016","unstructured":"Walz, J. M. et al. The German ROP Registry: Data from 90 infants treated for retinopathy of prematurity. Acta Ophthalmol. 94, e744\u2013e752 (2016).","journal-title":"Acta Ophthalmol."},{"key":"83985_CR9","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s00347-018-0701-5","volume":"115","author":"JM Walz","year":"2018","unstructured":"Walz, J. M. et al. Treated cases of retinopathy of prematurity in Germany: 5-year data from the Retina.net ROP registry. Ophthalmologe 115, 476\u2013488 (2018).","journal-title":"Ophthalmologe"},{"key":"83985_CR10","doi-asserted-by":"publisher","first-page":"e1033","DOI":"10.1111\/aos.13762","volume":"96","author":"K Trzcionkowska","year":"2018","unstructured":"Trzcionkowska, K. et al. Increase in treatment of severe retinopathy of prematurity following a new national guideline. Acta Ophthalmol. 96, e1033\u2013e1034 (2018).","journal-title":"Acta Ophthalmol."},{"key":"83985_CR11","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1136\/bjophthalmol-2013-304493","volume":"98","author":"AJ Van Sorge","year":"2014","unstructured":"Van Sorge, A. J. et al. Outcome and quality of screening in a nationwide survey on retinopathy of prematurity in the Netherlands. Br. J. Ophthalmol. 98, 1056\u20131060 (2014).","journal-title":"Br. J. Ophthalmol."},{"key":"83985_CR12","doi-asserted-by":"publisher","first-page":"e013366","DOI":"10.1136\/bmjopen-2016-013366","volume":"7","author":"GGW Adams","year":"2017","unstructured":"Adams, G. G. W. et al. Treatment trends for retinopathy of prematurity in the UK: Active surveillance study of infants at risk. BMJ Open 7, e013366 (2017).","journal-title":"BMJ Open"},{"key":"83985_CR13","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1001\/jamaophthalmol.2018.4290","volume":"136","author":"GE Quinn","year":"2018","unstructured":"Quinn, G. E. et al. Incidence and early course of retinopathy of prematurity: SECONDARY analysis of the postnatal growth and retinopathy of prematurity (G-ROP) study. JAMA Ophthalmol. 136, 1383\u20131389 (2018).","journal-title":"JAMA Ophthalmol."},{"key":"83985_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1542\/peds.2007-0644","volume":"121","author":"C Slidsborg","year":"2008","unstructured":"Slidsborg, C. et al. Treatment for retinopathy of prematurity in Denmark in a ten-year period (1996\u20132005): Is the incidence increasing?. Pediatrics 121, 97\u2013105 (2008).","journal-title":"Pediatrics"},{"key":"83985_CR15","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1016\/j.ophtha.2016.07.026","volume":"123","author":"JP Campbell","year":"2016","unstructured":"Campbell, J. P. et al. Plus disease in retinopathy of prematurity: A continuous spectrum of vascular abnormality as a basis of diagnostic variability. Ophthalmology 123, 2338\u20132344 (2016).","journal-title":"Ophthalmology"},{"key":"83985_CR16","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001719","author":"Y Yonekawa","year":"2017","unstructured":"Yonekawa, Y. et al. The cutting edge of retinopathy of prematurity care. Retina https:\/\/doi.org\/10.1097\/IAE.0000000000001719 (2017).","journal-title":"Retina"},{"key":"83985_CR17","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"HA Mintz-Hittner","year":"2011","unstructured":"Mintz-Hittner, H. A., Kennedy, K. A., Chuang, A. Z. & BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N. Engl. J. Med. 364, 603\u2013615 (2011).","journal-title":"N. Engl. J. Med."},{"key":"83985_CR18","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","volume":"132","author":"MM Geloneck","year":"2014","unstructured":"Geloneck, M. M. et al. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: A randomized clinical trial. JAMA Ophthalmol. 132, 1327\u20131333 (2014).","journal-title":"JAMA Ophthalmol."},{"key":"83985_CR19","doi-asserted-by":"publisher","first-page":"e20160057","DOI":"10.1542\/peds.2016-0057","volume":"137","author":"GE Quinn","year":"2016","unstructured":"Quinn, G. E. & Darlow, B. A. Concerns for development after bevacizumab treatment of ROP. Pediatrics 137, e20160057 (2016).","journal-title":"Pediatrics"},{"key":"83985_CR20","first-page":"CD009734","volume":"1","author":"MJ Sankar","year":"2018","unstructured":"Sankar, M. J., Sankar, J. & Chandra, P. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Cochrane Database Syst. Rev. 1, CD009734 (2018).","journal-title":"Cochrane Database Syst. Rev."},{"key":"83985_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jaapos.2017.10.006","volume":"22","author":"KA Kennedy","year":"2018","unstructured":"Kennedy, K. A. & Mintz-Hittner, H. A. Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity. J. AAPOS 22, 61-65.e1 (2018).","journal-title":"J. AAPOS"},{"key":"83985_CR22","doi-asserted-by":"publisher","first-page":"e20153218","DOI":"10.1542\/peds.2015-3218","volume":"137","author":"J Morin","year":"2016","unstructured":"Morin, J. et al. Neurodevelopmental outcomes following bevacizumab injections for retinopathy of prematurity. Pediatrics 137, e20153218 (2016).","journal-title":"Pediatrics"},{"key":"83985_CR23","doi-asserted-by":"publisher","first-page":"e0148019","DOI":"10.1371\/journal.pone.0148019","volume":"11","author":"R Lien","year":"2016","unstructured":"Lien, R. et al. Neurodevelopmental outcomes in infants with retinopathy of prematurity and bevacizumab treatment. PLoS ONE 11, e0148019 (2016).","journal-title":"PLoS ONE"},{"key":"83985_CR24","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.ophtha.2016.12.025","volume":"124","author":"DK VanderVeen","year":"2017","unstructured":"VanderVeen, D. K. et al. Anti-vascular endothelial growth factor therapy for primary treatment of type 1 retinopathy of prematurity: A report by the American Academy of Ophthalmology. Ophthalmology 124, 619\u2013633 (2017).","journal-title":"Ophthalmology"},{"key":"83985_CR25","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.ophtha.2017.08.005","volume":"125","author":"D Lepore","year":"2018","unstructured":"Lepore, D. et al. Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: Fluorescein angiographic findings. Ophthalmology 125, 218\u2013226 (2018).","journal-title":"Ophthalmology"},{"key":"83985_CR26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/IAE.0000000000001126","volume":"37","author":"B Lorenz","year":"2017","unstructured":"Lorenz, B. et al. Retinal vascular development with 0.312 mg intravitreal bevacizumab to treat severe posterior retinopathy of prematurity: A longitudinal fluorescein angiographic study. Retina 37, 97\u2013111 (2017).","journal-title":"Retina"},{"key":"83985_CR27","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","volume":"394","author":"A Stahl","year":"2019","unstructured":"Stahl, A. et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): An open-label randomised controlled trial. Lancet 394, 1551\u20131559 (2019).","journal-title":"Lancet"},{"key":"83985_CR28","doi-asserted-by":"publisher","first-page":"11894","DOI":"10.1038\/s41598-017-12264-z","volume":"7","author":"A Gotz-Wi\u0229ckowska","year":"2017","unstructured":"Gotz-Wi\u0229ckowska, A., Chmielarz-Czarnoci\u0144ska, A., Pawlak, M., Gadzinowski, J. & Mazela, J. Ranibizumab after laser photocoagulation failure in retinopathy of prematurity (ROP) treatment. Sci. Rep. 7, 11894 (2017).","journal-title":"Sci. Rep."},{"key":"83985_CR29","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.ophtha.2018.12.034","volume":"126","author":"AR Fielder","year":"2019","unstructured":"Fielder, A. R. et al. Describing retinopathy of prematurity: Current limitations and new challenges. Ophthalmology 126, 652\u2013654 (2019).","journal-title":"Ophthalmology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83985-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83985-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83985-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T04:03:02Z","timestamp":1670040182000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83985-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,25]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["83985"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-83985-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,25]]},"assertion":[{"value":"6 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4522"}}